Medical/Pharmaceuticals
Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy
Lunai Bioworks Announces Publication of Second-Generation Allogeneic Dendritic Cell Therapy Platform in the journal "Vaccines". LOS ANGELES, Nov. 6, 2025 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, has announced a major scientific breakthro...
2025-11-06 14:11
1457
THE ADECCO GROUP Q3 2025 RESULTS
AD HOC ANNOUNCEMENT pursuant to Art. 53 Listing Rules of SIX Swiss Exchange Strong share gains, good growth and improved profit margin ZURICH, Nov. 6, 2025 /PRNewswire/ -- HIGHLIGHTS * Further strong market share gains, Group +375 bps and Adecco +300 bps * Group revenues +3.4% yoy, and +3...
2025-11-06 13:45
1056
Alphamab Oncology Showcases Cutting-edge Breakthroughs and Innovative Achievements at the 16th World ADC San Diego
SUZHOU, China, Nov. 6, 2025 /PRNewswire/ -- The 16th World ADC San Diego, held from November 3–6, 2025, brought together industry leaders inSan Diego, USA. Dr. Ting Xu, Founder, Chairman, and CEO of Alphamab Oncology, was invited to deliver a presentation titled "JSKN021: EGFR/HER3 Targeted Dual-...
2025-11-06 12:05
1569
The 2025 Chinese Congress on Holistic Integrative Oncology (CCHIO) will be held in Kunming, presenting a new landscape of integrated cancer prevention and treatment from a global perspective.
KUNMING, China, Nov. 5, 2025 /PRNewswire/ -- From November 6 to 9, 2025, the highly anticipated 2025 CCHIO will be grandly held in Kunming, the "Spring City". Hosted by the Chinese Anti-Cancer Association and the Secretariat of the Tengchong Scientists Forum Organizing Committee, co-hosted by the...
2025-11-06 10:58
1149
New Regional Certifications to Boost Healthcare Training Standards Across Southeast Asia
* Two new specially designed certification programmes will train doctors, nurses and technical specialists across the region in simulation-based medical education. SINGAPORE, Nov. 6, 2025 /PRNewswire/ -- The first healthcare simulation certification programmes designed specifically for Southeas...
2025-11-06 10:13
1172
The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
CorrectSequence Therapeutics' CS-121 Completed Dosing of First Chylomicronemia
Patient, Demonstrating Excellent Safety and Significant Efficacy
SHANGHAI, Nov. 6, 2025 /PRNewswire/ -- On November 6, 2025, Shanghai,
China, CorrectSequence Therapeutics Co., Ltd. (Correctseq
2025-11-06 08:00
1349
BioDlink Congratulates Lepu Biopharma on Securing Approval for the World's First Approved EGFR-Targeted ADC
* BioDlink helps Lepu Biopharma win China's marketing approval for EGFR-targeted ADC treating recurrent or metastatic nasopharyngeal carcinoma * This Becotatug Vedotin injection approval is BioDlink's first commercial ADC manufacturing initiative worldwide, validating its complex biologics co...
2025-11-05 21:00
1543
IDT Biologika Accelerates Global CDMO Expansion Manufacturing capabilities highlighted through consecutive participation in WVC, CPHI and BIO-Europe 2025
* Showcased end-to-end, customized manufacturing capabilities covering vaccines, gene and immune therapeutics * Strengthening global CDMO strategy through strategic synergy with SK bioscience * Sustainable growth expected, backed by European commercial manufacturing infrastructure and regul...
2025-11-05 21:00
1850
Nona Biosciences Announces Expansion of Collaboration with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies
CAMBRIDGE, Mass., Nov. 5, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I™), today announced an evaluation and license agreement with Umoja Biopharma ("Umoja"), the clinical-stage leader of in vivo cell therapies that...
2025-11-05 20:07
1111
HanchorBio Presents Preclinical Data on HCB301 at SITC 2025
HCB301 is a first-in-class tri-specific immunotherapy targeting SIRPα-CD47, PD-1/PD-L1, and TGFβ; it shows potent macrophage activation, T-cell restoration, and tumor microenvironment remodeling in preclinical solid tumor models. TAIPEI, SHANGHAI, and SAN FRANCISCO, Nov. 5, 2025 /PRNewswire/ -- ...
2025-11-05 20:00
2805
XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance Bispecific Antibody Development
SHANGHAI, Nov. 5, 2025 /PRNewswire/ -- Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced a strategic platform-based collaboration with Eli Lilly and Company ("Lilly") to accelerate the discovery and...
2025-11-05 18:00
1383
SingHealth Duke-NUS Launches Two New Global Health Centres to Advance Allied Health and Pharmacy Practices in Asia
* The Centre for Global Allied Health and Centre for Global Pharmacy will advance global health collaboration and capacity building, with a focus on strengthening allied health and pharmacy practices acrossAsia. * Both centres build on a legacy of more than 120 global health projects led by S...
2025-11-05 15:43
1071
KLN Appointed by Ego Pharmaceuticals as 4PL Partner in Hong Kong Strategic Collaboration to Deliver End-to-End Healthcare Supply Chain Solutions
HONG KONG, Nov. 5, 2025 /PRNewswire/ -- KLN Logistics Group Limited ('KLN'; Stock Code 0636.HK) is pleased to announce the appointment of its pharmaceutical arm, KLN Pharma (Hong Kong) Limited ('KLN Pharma'), as the fourth-party logistics (4PL) service provider for Australian skincare brand Ego ...
2025-11-05 13:42
1041
Ascletis Presents Full Analysis of Phase Ib Study of ASC30 Oral Tablet, Phase Ib Study of ASC30 Injection, and Preclinical Study of Combination of ASC31 and ASC47 at ObesityWeek® 2025
-Positive data from Phase Ib study of ASC30 oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction; safe and well tolerated with only mild-to-moderate gastrointestinal (GI) adverse events (AEs) across all multiple ascending dose (MAD) cohorts. -Phase Ib study data of ASC...
2025-11-05 08:10
1663
Mölnlycke® establishes first wound care manufacturing site in China
CHANGSHU, China and GOTHENBURG, Sweden, Nov. 5, 2025 /PRNewswire/ -- Mölnlycke® Health Care, a global leader in MedTech, headquartered inGothenburg, Sweden, is celebrating the commencement of its new wound care manufacturing site in Changshu,China. This strategic investment marks a milestone in M...
2025-11-05 08:00
1171
INTREPID Alliance Launches Antiviral Toolbox to Support Global Research Community
Open-access resource includes Registry of Antiviral Compound Libraries to help catalyze drug discovery for priority viruses of pandemic and endemic concern CAMBRIDGE, Mass., Nov. 5, 2025 /PRNewswire/ -- The INTREPID Alliance today announced the launch of theAntiviral Toolbox, an open-access resou...
2025-11-05 02:20
1043
Metabolon Powers Largest-Ever Veteran Metabolomics Study with Global Discovery Panel
Metabolon to Support Landmark Million Veteran Program 62,000-sample Dataset
AdvancingVeteran Health and Multiomics Research
MORRISVILLE, N.C., Nov. 4, 2025 /PRNewswire/ -- Metabolon
2025-11-04 22:00
967
Grit Biotherapeutics Invited to Deliver Oral Presentation at ASH 2025 on Breakthrough In Vivo CAR-T Therapy GT801
BEIJING, Nov. 4, 2025 /PRNewswire/ -- Grit Biotherapeutics Co., Ltd. ("Grit Bio "), a leading clinical-stage biopharmaceutical company pioneering next-generation immunotherapies,today announced that its groundbreaking GT801 in vivo CAR-T program has been selected for an oral presentation at the u...
2025-11-04 21:15
1684
LakeShore Biopharma Enters into Definitive Agreement for Going-Private Transaction
BEIJING, Nov. 4, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics fo...
2025-11-04 20:04
2764
Sky Labs Attracts Investment With Omron Subsidiary 'OMRON VENTURES'
Global blood pressure monitoring No. 1 OMRON Healthcare signs strategic partnership MoU SEOUL, South Korea, Nov. 4, 2025 /PRNewswire/ -- On November 4, 2025, Sky Labs announced that it had attracted investments with OMRON Ventures(OVC: Minato-ku, Tokyo), Omron Group's enterprise-led venture capit...
2025-11-04 19:25
1664
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 328 media titles]
2026-02-19 14:30
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 327 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 302 media titles]
2026-02-24 16:13
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 288 media titles]
2026-02-23 10:09
Most Read
/C O R R E C T I O N -- Republic Power Group Limited (NASDAQ: RPGL)/
2026-02-20 06:36
8845